

Dolores R Serrano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2622244/publications.pdf>

Version: 2024-02-01

81
papers

2,405
citations

186265

28
h-index

223800

46
g-index

81
all docs

81
docs citations

81
times ranked

3211
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-assembling, supramolecular chemistry and pharmacology of amphotericin B: Poly-aggregates, oligomers and monomers. <i>Journal of Controlled Release</i> , 2022, 341, 716-732.	9.9	24
2	Harnessing the Antibacterial Properties of Fluoridated Chitosan Polymers against Oral Biofilms. <i>Pharmaceutics</i> , 2022, 14, 488.	4.5	4
3	Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment. <i>Pharmaceutics</i> , 2022, 15, 435.	3.8	14
4	Tailoring Rational Manufacturing of Extemporaneous Compounding Oral Dosage Formulations with a Low Dose of Minoxidil. <i>Pharmaceutics</i> , 2022, 14, 658.	4.5	1
5	Enhancing the antibacterial effect of chitosan to combat orthopaedic implant-associated infections. <i>Carbohydrate Polymers</i> , 2022, 289, 119385.	10.2	16
6	Antibiotic stability in portable elastomeric infusion devices: A systematic review. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1355-1368.	1.0	7
7	Traction of 3D and 4D Printing in the Healthcare Industry: From Drug Delivery and Analysis to Regenerative Medicine. <i>ACS Biomaterials Science and Engineering</i> , 2022, 8, 2764-2797.	5.2	34
8	3D printed spherical mini-tablets: Geometry versus composition effects in controlling dissolution from personalised solid dosage forms. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120336.	5.2	53
9	Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis. <i>Journal of Immunology Research</i> , 2021, 2021, 1-13.	2.2	7
10	Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?. <i>Diseases (Basel)</i> , 2021, 9, 50382.	2.5	10
11	Understanding Direct Powder Extrusion for Fabrication of 3D Printed Personalised Medicines: A Case Study for Nifedipine Minitablets. <i>Pharmaceutics</i> , 2021, 13, 1583.	4.5	26
12	Topical Delivery of Amphotericin B Utilizing Transferosomes for the Treatment of Cutaneous Leishmaniasis. <i>Proceedings (mdpi)</i> , 2021, 78, 26.	0.2	1
13	Engineering 3D Printed Microfluidic Chips for the Fabrication of Nanomedicines. <i>Pharmaceutics</i> , 2021, 13, 2134.	4.5	16
14	Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale. <i>International Journal of Pharmaceutics</i> , 2020, 573, 118817.	5.2	118
15	Effect of enantiomerism on the bioequivalence of a new ibuprofen 600 mg tablet formulation obtained by roller compaction. <i>Chirality</i> , 2020, 32, 185-190.	2.6	2
16	Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis. <i>International Journal of Pharmaceutics</i> , 2020, 588, 119734.	5.2	19
17	Preformulation Studies of a Stable PTEN-PDZ Lipopeptide Able to Cross an In Vitro Blood-Brain-Barrier Model as a Potential Therapy for Alzheimer's Disease. <i>Pharmaceutical Research</i> , 2020, 37, 183.	3.5	5
18	Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases. <i>ACS Infectious Diseases</i> , 2020, 6, 2647-2660.	3.8	21

#	ARTICLE	IF	CITATIONS
19	Nucleotides and AHCC Enhance Th1 Responses In Vitro in Leishmania-Stimulated/Infected Murine Cells. <i>Molecules</i> , 2020, 25, 3918.	3.8	3
20	Oral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing. <i>Pharmaceutical Research</i> , 2020, 37, 132.	3.5	34
21	Engineering butylglyceryl-modified polysaccharides towards nanomedicines for brain drug delivery. <i>Carbohydrate Polymers</i> , 2020, 236, 116060.	10.2	18
22	Evaluating the Potential of Ursolic Acid as Bioproduct for Cutaneous and Visceral Leishmaniasis. <i>Molecules</i> , 2020, 25, 1394.	3.8	14
23	Transcutaneous anaesthetic nano-enabled hydrogels for eyelid surgery. <i>International Journal of Pharmaceutics</i> , 2020, 577, 119003.	5.2	10
24	Personalised 3D Printed Medicines: Optimising Material Properties for Successful Passive Diffusion Loading of Filaments for Fused Deposition Modelling of Solid Dosage Forms. <i>Pharmaceutics</i> , 2020, 12, 345.	4.5	50
25	Antifungal and Antiparasitic Drug Delivery. <i>Pharmaceutics</i> , 2020, 12, 324.	4.5	1
26	Designing Fast-Dissolving Orodispersible Films of Amphotericin B for Oropharyngeal Candidiasis. <i>Pharmaceutics</i> , 2019, 11, 369.	4.5	34
27	Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis. <i>Pharmaceutics</i> , 2019, 11, 353.	4.5	18
28	Increased Efficacy of Oral Fixed-Dose Combination of Amphotericin B and AHCC® Natural Adjuvant against Aspergillosis. <i>Pharmaceutics</i> , 2019, 11, 456.	4.5	9
29	Predicting the critical quality attributes of ibuprofen tablets via modelling of process parameters for roller compaction and tableting. <i>International Journal of Pharmaceutics</i> , 2019, 565, 209-218.	5.2	22
30	Tuning the Transdermal Delivery of Hydroquinone upon Formulation with Novel Permeation Enhancers. <i>Pharmaceutics</i> , 2019, 11, 167.	4.5	13
31	Technology-enhanced learning in higher education: How to enhance student engagement through blended learning. <i>European Journal of Education</i> , 2019, 54, 273-286.	2.8	73
32	Use of leucine to improve aerodynamic properties of ciprofloxacin-loaded maltose microparticles for inhalation. <i>European Journal of Pharmaceutical Research</i> , 2019, 1, 02-11.	1.0	20
33	New aerosol formulation to control ciprofloxacin pulmonary concentration. <i>Journal of Controlled Release</i> , 2018, 271, 118-126.	9.9	21
34	Efficacy of a poly-aggregated formulation of amphotericin B in treating systemic sporotrichosis caused by <i>Sporothrix brasiliensis</i> . <i>Medical Mycology</i> , 2018, 56, 288-296.	0.7	9
35	Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia. <i>Journal of Controlled Release</i> , 2018, 270, 135-144.	9.9	51
36	Production of cocrystals in an excipient matrix by spray drying. <i>International Journal of Pharmaceutics</i> , 2018, 536, 467-477.	5.2	42

#	ARTICLE	IF	CITATIONS
37	Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 124, 13-27.	4.3	34
38	New Drugs and Therapeutic/Diagnostic Targets for Fungal and Parasitic Diseases - Part II. Current Topics in Medicinal Chemistry, 2018, 18, 1357-1357.	2.1	0
39	New Drugs and Therapeutic/Diagnostic Targets for Fungal and Parasitic Diseases - Part I. Current Topics in Medicinal Chemistry, 2018, 18, 1274-1274.	2.1	1
40	A multivariate investigation into the relationship between pharmaceutical characteristics and patient preferences of bioequivalent ibuprofen tablets. Patient Preference and Adherence, 2018, Volume 12, 1927-1935.	1.8	9
41	Engineering of pharmaceutical cocrystals in an excipient matrix: Spray drying versus hot melt extrusion. International Journal of Pharmaceutics, 2018, 551, 241-256.	5.2	47
42	Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis. Molecular Pharmaceutics, 2018, 15, 2570-2583.	4.6	39
43	Nanotechnology in Brain Tumor Targeting. , 2018, , 111-145.		3
44	Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme. Materials, 2018, 11, 779.	2.9	71
45	Applying Loop-mediated Isothermal Amplification (LAMP) in the Diagnosis of Malaria, Leishmaniasis and Trypanosomiasis as Point-of-Care Tests (POCTs). Current Topics in Medicinal Chemistry, 2018, 18, 1358-1374.	2.1	9
46	Engineering Oral and Parenteral Amorphous Amphotericin B Formulations against Experimental <i>Trypanosoma cruzi</i> Infections. Molecular Pharmaceutics, 2017, 14, 1095-1106.	4.6	21
47	Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting. International Journal of Pharmaceutics, 2017, 525, 139-148.	5.2	52
48	Oral amphotericin B: The journey from bench to market. Journal of Drug Delivery Science and Technology, 2017, 42, 75-83.	3.0	21
49	Effect of the characteristics of raw material ibuprofen on roller compaction and dissolution. Journal of Drug Delivery Science and Technology, 2017, 42, 237-244.	3.0	9
50	Analgesic and anti-inflammatory controlled-released injectable microemulsion: Pseudo-ternary phase diagrams, in vitro , ex vivo and in vivo evaluation. European Journal of Pharmaceutical Sciences, 2017, 101, 220-227.	4.0	16
51	A Comparative Study on the Performance of Inert and Functionalized Spheres Coated with Solid Dispersions Made of Two Structurally Related Antifungal Drugs. Molecular Pharmaceutics, 2017, 14, 3718-3728.	4.6	9
52	Personalised 3D Printed Medicines: Which Techniques and Polymers Are More Successful?. Bioengineering, 2017, 4, 79.	3.5	164
53	Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?. Annals of Translational Medicine, 2017, 5, 448-448.	1.7	10
54	Engineering Synergistically Active and Bioavailable Cost-effective Medicines for Neglected Tropical Diseases; The Role of Excipients. Current Topics in Medicinal Chemistry, 2017, 17, .	2.1	6

#	ARTICLE	IF	CITATIONS
55	Cocrystal habit engineering to improve drug dissolution and alter derived powder properties. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 665-677.	2.4	55
56	Developing transcutaneous nanoenabled anaesthetics for eyelid surgery. <i>British Journal of Ophthalmology</i> , 2016, 100, 871-876.	3.9	16
57	Modelling and shadowgraph imaging of cocrystal dissolution and assessment of in vitro antimicrobial activity for sulfadimidine/4-aminosalicylic acid cocrystals. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 89, 125-136.	4.0	41
58	Impact of Substrate Properties on the Formation of Spherulitic Films: A Case Study of Salbutamol Sulfate. <i>Crystal Growth and Design</i> , 2016, 16, 3853-3858.	3.0	8
59	Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels – A Strategy for Brain Cancer Treatments. <i>Pharmaceutical Research</i> , 2016, 33, 1289-1303.	3.5	29
60	Unresponsiveness of Experimental Canine Leishmaniosis to a New Amphotericin B Formulation. <i>Advances in Pharmaceutics</i> , 2015, 2015, 1-13.	0.5	3
61	Editorial (Thematic Issue: Engineering Nanomedicines into Safe and Effective Therapeutics). <i>Current Topics in Medicinal Chemistry</i> , 2015, 15, 2253-2253.	2.1	2
62	Detecting polymeric nanoparticles with coherent anti-stokes Raman scattering microscopy in tissues exhibiting fixative-induced autofluorescence. <i>Proceedings of SPIE</i> , 2015, , .	0.8	1
63	Oral Particle Uptake and Organ Targeting Drives the Activity of Amphotericin B Nanoparticles. <i>Molecular Pharmaceutics</i> , 2015, 12, 420-431.	4.6	91
64	Polymorphism in Sulfadimidine/4-Aminosalicylic Acid Cocrystals: Solid-State Characterization and Physicochemical Properties. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 1385-1398.	3.3	49
65	Peptide Self-Assemblies for Drug Delivery. <i>Current Topics in Medicinal Chemistry</i> , 2015, 15, 2277-2289.	2.1	53
66	Emerging Nanonisation Technologies: Tailoring Crystalline Versus Amorphous Nanomaterials. <i>Current Topics in Medicinal Chemistry</i> , 2015, 15, 2327-2340.	2.1	25
67	Strategies To Deliver Peptide Drugs to the Brain. <i>Molecular Pharmaceutics</i> , 2014, 11, 1081-1093.	4.6	133
68	Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3268-3274.	3.0	23
69	New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and <i>Leishmania</i> spp. <i>International Journal of Pharmaceutics</i> , 2014, 473, 148-157.	5.2	63
70	Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations. <i>International Journal of Pharmaceutics</i> , 2013, 447, 38-46.	5.2	64
71	Amphotericin B Formulations – The Possibility of Generic Competition. <i>Pharmaceutical Nanotechnology</i> , 2013, 1, 250-258.	1.5	24
72	Peptide pills for brain diseases? Reality and future perspectives. <i>Therapeutic Delivery</i> , 2013, 4, 479-501.	2.2	20

#	ARTICLE	IF	CITATIONS
73	The oral delivery of amphotericin B. <i>Therapeutic Delivery</i> , 2013, 4, 9-12.	2.2	24
74	Active Targeting. , 2013, , 337-374.		0
75	The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/- Pharmacodynamics of Proton Pump Inhibitor-Containing <i>Helicobacter pylori</i> Treatments. <i>Current Drug Metabolism</i> , 2012, 13, 1303-1312.	1.2	17
76	A novel formulation of solubilised amphotericin B designed for ophthalmic use. <i>International Journal of Pharmaceutics</i> , 2012, 437, 80-82.	5.2	22
77	A Prodrug Nanoparticle Approach for the Oral Delivery of a Hydrophilic Peptide, Leucine ⁵ -enkephalin, to the Brain. <i>Molecular Pharmaceutics</i> , 2012, 9, 1665-1680.	4.6	64
78	Imaging cortical vasculature with stimulated Raman scattering and two-photon photothermal lensing microscopy. <i>Journal of Raman Spectroscopy</i> , 2012, 43, 668-674.	2.5	33
79	Exploring uptake mechanisms of oral nanomedicines using multimodal nonlinear optical microscopy. <i>Journal of Biophotonics</i> , 2012, 5, 458-468.	2.3	62
80	Amphiphilic poly(l-amino acids) – New materials for drug delivery. <i>Journal of Controlled Release</i> , 2012, 161, 523-536.	9.9	138
81	Chapter 7.1. Nanostructures Overcoming the Blood-Brain Barrier: Physiological Considerations and Mechanistic Issues. <i>RSC Drug Discovery Series</i> , 2012, , 329-363.	0.3	5